Global Viral Vaccines CDMO Market Size & Trends Report Segmented by Vaccine Type (Attenuated, Inactivated, Subunit, DNA Vaccines), Service Type (Process Development, Upstream/Downstream Development, Analytical Testing, Fill-Finish, Packaging/Labelling), End User & Regional Forecast to 2031

1. Introduction
   • Introduction​
   • Market Scope​
     • Market Definition​
     • Segments Covered​
     • Regional Segmentation​
   • Research Timeframe​
   • Currency Considered​
   • Study Limitations​
   • Stakeholders​
   • List of Abbreviations​
   • Key Conferences and Events (2026-2027)​
2. Research Methodology​
   • Secondary Research​
   • Primary Research​
   • Market Estimation​
     • Bottom-Up Approach​
     • Top-Down Approach​
   • Market Forecasting​
3. Executive Summary
   • Viral Vaccines CDMO Market Snapshot (2026-2031)​
   • Segment Overview​
   • Regional Snapshot​
   • Competitive Insights ​

4. Market Overview
   • Market Dynamics
     • Drivers
       • Escalating global burden of infectious diseases
       • Surge in outsourcing start-to-end drug development services
       • Accelerated adoption of the mRNA and viral vector platforms
       • Expanding government-funded vaccine manufacturing initiatives
       • Growing need for specialized CDMO services for new viral vaccine technologies
     • Restraints​
       • Stringent regulatory compliance and GMP certification barrier
       • High capital intensity and infrastructure complexity
       • Skilled workforce scarcity in viral manufacturing disciplines
     • Opportunities​
       • Rising viral vector manufacturing
       • Growing adoption of single-use bioreactor systems
       • Integration of continuous bioprocessing technologies
       • Untapped potential in the emerging market
     • Key Market Trends
       • Increased focus on cold chain and lyophilization capabilities
       • Shift towards risk sharing and outcome-based CDMO contract structures
     • Unmet Market Needs​
     • Industry Speaks​

5. Global Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Vaccine Type, USD Billion
   • Introduction​
   • Attenuated Vaccine
   • Inactivated Vaccine
   • DNA Vaccines
   • Subunit Vaccines

6. Global Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Service Type, USD Billion
   • Introduction​
   • Formulation & Process Development
   • Upstream Development
   • Downstream Development
   • Analytical Testing
   • Fill-Finish Services
   • Packaging & Labeling
   • Others

7. Global Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Workflow, USD Billion
   • Introduction
   • Clinical
   • Commercial

8. Global Viral Vaccines CDMO Market Size & Forecast (2024-2031), By End User, USD Billion
   • Introduction
   • Pharmaceutical and Biopharmaceutical Companies
   • Academic and Research Institute
   • Other End Users

9. Global Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Region, USD Billion
   • Introduction​
   • North America Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Country, USD Billion​
     • US​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Canada​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
   • Europe Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Country, USD Billion​
     • UK ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Germany ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​)
     • France ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Italy ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Spain ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Rest of Europe ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
   • Asia Pacific (APAC) Viral Vaccines CDMO Market Size & Forecast (2024-2031), By Country, USD Billion​
     • China ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Japan ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • India ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
     • Rest of Asia Pacific ​
       • Market Size & Forecast, By Vaccine Type (USD Billion)​
       • Market Size & Forecast, By Service Type (USD Billion)​
       • Market Size & Forecast, By Workflow (USD Billion)​
       • Market Size & Forecast, By End User (USD Billion)​
   • Latin America (LATAM) Viral Vaccines CDMO Market Size & Forecast (2024-2031), USD Billion​
     • Market Size & Forecast, By Vaccine Type (USD Billion)​
     • Market Size & Forecast, By Service Type (USD Billion)​
     • Market Size & Forecast, By Workflow (USD Billion)​
     • Market Size & Forecast, By End User (USD Billion)​
   • Middle East & Africa (MEA) Viral Vaccines CDMO Market Size & Forecast (2024-2031), USD Billion​
     • Market Size & Forecast, By Vaccine Type (USD Billion)​
     • Market Size & Forecast, By Service Type (USD Billion)​
     • Market Size & Forecast, By Workflow (USD Billion)​
     • Market Size & Forecast, By End User (USD Billion)​

10. Competitive Landscape
    • Key Players and their Competitive Positioning
      • Key Player Comparison
      • Segment-wise Player Mapping
      • Market Share Analysis (2025)
      • Company Categorization Matrix
        • Dominants/Leaders
        • New Entrants
        • Emerging Players
        • Innovative Players
    • Key Strategies Assessment, By Player (2023-2026)
      • New Product/Service Launch
      • Partnerships, Agreements, & Collaborations
      • Mergers & Acquisitions
      • Geographic Expansion

11. Company Profiles*

(Business Overview, Financial Performance**, Products/Services Offered, Recent Developments)

• Lonza Group
• Catalent Pharma
• Thermo Fisher Scientific, Inc.
• Alcami Corporation
• Samsung Biologics
• Fujifilm Diosynth Biotechnologies
• WuXi Biologics
• Recipharm AB
• HALIX B.V
• Batavia Biosciences B.V
• Other Prominent Players

Note: *Indicative list

**For listed companies